How do COVID booster side effects compare to those from the original vaccine series?

Booster doses generally produce similar types of adverse events to the primary series — injection site reactions, fatigue, headache, muscle aches — though the pattern varies by vaccine type and individual factors. The MJA study published in June 2026 specifically examined boosters (not the primary series) in Australians who received them between 2023 and 2024. It found around 30% reported at least one adverse event, with most resolving within 3 days and fewer than 2.5% requiring medical care. Some individuals find booster reactions milder than their initial doses; others find them similar or slightly more noticeable. Prior personal experience with vaccination remains a useful predictor for what you are likely to experience.

When should I seek medical attention after a COVID booster?

Most post-booster reactions are expected immune responses that resolve within 1–3 days and do not require medical attention. Seek care if you experience: high fever not responding to paracetamol, significant chest pain or pressure, difficulty breathing or shortness of breath, an unusual or rapidly spreading rash, symptoms that are severe, worsening after 3 days, or lasting more than 4–5 days. Myocarditis (inflammation of the heart muscle) is a rare but recognised adverse event, particularly in younger males after mRNA vaccines — chest pain, pressure, or shortness of breath in the days following vaccination warrants prompt review. These serious reactions are uncommon but real, and the right response is assessment rather than waiting.

COVID boosters: 30% of Australians get side effects, most resolve in 3 days

What just happened

A survey study published in the Medical Journal of Australia (Volume 224, June 2026) has produced the most comprehensive Australian-specific data yet on what happens after a COVID-19 booster dose.

The researchers — led by investigators at the National Centre for Immunisation Research and Surveillance (NCIRS) — analysed 197,476 survey responses from adults who received COVID booster vaccinations in Australia between January 2023 and August 2024.

The question they were answering is one many patients ask before booking a booster: what is actually going to happen to me in the next few days?

The both-and

What the data shows

Approximately 30% of participants reported at least one adverse event following their booster. The two most common:

Injection site reactions (pain, redness, swelling at the injection site): 23.8%
Fatigue: 19.4%

Systemic effects — headache, muscle aches, chills, fever — were reported at lower frequencies. By day 3, roughly 70% of those who experienced any adverse event had fully resolved symptoms.

Two numbers matter most here:

Fewer than 2.5% sought medical care for their reaction
Only 5.6% reported any disruption to daily activities

This is not trivial. If you are in the 30% who experience something, that is real and it matters. But the overall picture from this dataset is that serious or prolonged reactions requiring medical attention are uncommon — affecting fewer than 1 in 40 people across a large and representative Australian cohort.

The variation is real — and clinically important

One of the most useful findings in the MJA study is how much adverse event rates varied by age, sex, and vaccine type: from as low as 12% in some groups to 75.5% in others.

That range — 12% to 75.5% — tells you that “30% get side effects” is a population average that may not accurately represent your individual situation. A younger woman receiving a specific mRNA booster formulation has a statistically higher likelihood of local and systemic reactions than an older man receiving a different product. Neither person’s experience is wrong; they are likely to have genuinely different immune responses.

This pattern is consistent with what is known from Australian vaccine safety surveillance generally. Younger age is associated with more vigorous immune responses — and more noticeable post-vaccination symptoms — partly because younger immune systems mount larger initial reactions, and partly because younger people tend to be more physically sensitive to those responses. Women also report post-vaccination reactions at higher rates than men across vaccine types, which may reflect both genuine immunological differences and reporting differences.

Neither of these patterns means younger women should avoid boosters. It means they should be counselled differently — with a more accurate picture of what to expect — than older men, or than any individual whose prior vaccine history is available as a predictor.

What this data does and doesn’t tell us

What it tells us: for the large majority of Australians getting COVID boosters in the 2023–2024 era, the short-term adverse event profile was manageable, self-limiting, and not requiring medical care. That is reassuring for a population weighing whether to book their next dose.

What it doesn’t tell us: it doesn’t address long-term effects, rare serious adverse events that require much larger datasets or dedicated pharmacovigilance programmes to capture (myocarditis, anaphylaxis, and other rare reactions are tracked through AusVaxSafety separately), or the clinical question of whether and when to get a booster in the first place.

It also uses a survey design, which means reported adverse events from people who chose to respond. Response rates and self-selection effects can influence results in both directions, and the numbers should be read as indicative rather than precise. They are the best Australian-specific data currently available.

The clinical conversation this enables

Right now, many people receive a booster recommendation from their GP without much accompanying information about what to expect. The consultation often goes: “You’re due for a booster” → script → done. This MJA study gives both GPs and patients something more concrete.

For patients: knowing that approximately 1 in 3 people notice some reaction, that it is most likely to peak in the first 24–48 hours, and that symptoms typically resolve within 3 days — that is useful planning information. Scheduling a booster on a Thursday rather than a Monday avoids the worst-case scenario of feeling flat on a workday morning. Having paracetamol at home is sensible preparation. Resting if you need to is appropriate, not a sign that something went wrong.

For GPs: the age and sex stratification in the study is an opportunity to move from “most people get a bit of soreness” to “based on your profile, here is what’s more and less likely for you specifically.”

2 cents

The question I hear most from patients in their 40s and 50s about COVID boosters isn’t “does it work?” — it’s “is it going to knock me around?” This study offers a better answer than “it varies.”

For most people in this age group, the data suggests: you are more likely to notice something than not, it is most likely to be local soreness or fatigue, and you will almost certainly be back to normal within three days. If you have had previous boosters without significant reactions, that is your best personal predictor — prior response is informative.

The 2.5% who needed medical care are important to acknowledge. If you develop high fever not responding to simple analgesia, significant chest pain, shortness of breath, or symptoms that are severe, spreading, or lasting more than three to four days post-booster, those warrant medical review — not waiting. These are uncommon but real, and the right response is assessment.

Whether and when to get your next COVID booster is a conversation worth having with your GP in the context of your individual health, current immunity, and the variant landscape. This study helps you have that conversation with clearer expectations on both sides.

This is general health information and does not constitute individual clinical advice.

Verdict

Verdict: yes — worth knowing about.

The largest Australian-specific survey on COVID booster safety gives clinicians and patients shared, data-grounded language for what to expect. The picture is reassuring for most: short-lived, self-limiting reactions are common, medical care is rarely needed, and disruption to daily life is the exception rather than the rule. The variation by age and sex is a reminder that personalised counselling beats generic reassurance — and that the answer to “what will happen to me?” depends on more than the average.